Please assess the completion status of the following clinical trial:

Trial Title: Safety of Simvastatin in LAM and TSC

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Female, age 18 and older with clinically definitive diagnosis (biopsy proven or compatible chest CT/MRI scan) of sporadic LAM (LAM-S) or LAM associated with TS (LAM-TS).~* Treated with a stable (at least 3 months) dose of sirolimus or everolimus~* Negative pregnancy test (women of child bearing potential) at screening.~* Women of childbearing potential must be using barrier, medically acceptable contraceptive precautions.~* Signed and dated informed consent.~Exclusion Criteria:~* Age \< 18 years~* Known allergy to simvastatin or currently taking simvastatin, or therapy with a medication in the same class as simvastatin within the past 30 days.~* Allergy to sirolimus or everolimus.~* Current use of other than sirolimus or everolimus investigational drug for TSC or LAM within the past 30 days.~* Use of estrogen containing medications, including birth control pills, within the 30 days prior to enrollment.~* Treatment with drugs having known metabolic interactions with statin drugs (e.g. cytochrome P450 3A4 metabolism), including ketoconazole, itraconazole, fluconazole, erythromycin, clarithromycin, azithromycin, niacin (nicotinic acid), digoxin, warfarin, sildenafil or use of strong CYP3A4 inhibitors including gemfibrozil, cyclosporine, danazol, verapamil, diltiazem, and dronedarone. amiodarone, amlodipine, and ranolazine.~* Participation in another clinical study(ies) of an investigational treatment or drug within 30 days prior to the screening visit.~* Amiodarone; within the past 30 days.~* Significant dysfunction of liver (ALT \> 2 times upper limit of normal-ULN), kidney (serum creatinine \> 1.5 times ULN), or blood (leucopenia (ANC\<2000), anemia, Hgb \< 11 gm/dl).~* History of inflammatory muscle disease or myopathy.~* Bleeding diathesis or anticoagulant therapy.~* Uncontrolled hyperlipidemia or diabetes.~* Pregnant, breast feeding, or plan to become pregnant within the next 6 months~* Inadequate contraception (must agree to barrier method)~* History of organ transplant.~* Active on transplant list.~* Severe or uncontrolled medical conditions which would cause an unacceptable safety risk or compromise compliance with the protocol.~* Unstable seizures (recent changes in pattern or anti-epileptics).~* Mental illness or cognitive deficit precluding informed consent..~* Inability to attend scheduled clinic visits or comply with study procedures.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- simvastatin treatment arm (Type: EXPERIMENTAL): Eligible patients on sirolimus or everolimus will be assigned to receive 20 mg of simvastatin once daily for a period of two months. If tolerated, the dosage of simvastatin will be advanced to 40 mg once daily in months 3 and 4.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete